X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (150) 150
index medicus (115) 115
animals (86) 86
mice (57) 57
sialic acid binding ig-like lectin 2 - antagonists & inhibitors (44) 44
hematology (39) 39
immunology (37) 37
antibodies, monoclonal - therapeutic use (34) 34
sialic acid binding ig-like lectin 2 - immunology (34) 34
female (32) 32
oncology (31) 31
cell line, tumor (30) 30
cd22 (29) 29
male (28) 28
article (24) 24
b-lymphocytes - immunology (24) 24
ligands (24) 24
cancer (23) 23
immunotherapy (23) 23
lectins (22) 22
antigens, cd - metabolism (21) 21
chemotherapy (20) 20
sialic acid binding ig-like lectin 2 - metabolism (20) 20
biochemistry & molecular biology (19) 19
sialic acid binding ig-like lectin 2 (19) 19
antigens, cd - immunology (18) 18
flow cytometry (18) 18
immune system (18) 18
analysis (17) 17
antibodies, monoclonal, humanized - therapeutic use (17) 17
adult (16) 16
antineoplastic agents - therapeutic use (16) 16
b-lymphocytes - drug effects (16) 16
gene expression (16) 16
leukemia (16) 16
research (16) 16
sialic acid binding ig-like lectin 3 - metabolism (16) 16
abridged index medicus (15) 15
antineoplastic agents - pharmacology (15) 15
apoptosis (15) 15
cell biology (15) 15
expression (15) 15
gemtuzumab ozogamicin (15) 15
binding (14) 14
medicine, research & experimental (14) 14
mice, inbred c57bl (14) 14
monoclonal antibodies (14) 14
monoclonal-antibody (14) 14
proteins (14) 14
rituximab (14) 14
sialic acid binding ig-like lectin 3 (14) 14
therapy (14) 14
activation (13) 13
aged (13) 13
antibodies, monoclonal - pharmacology (13) 13
antibodies, monoclonal, humanized - pharmacology (13) 13
cd22 antigen (13) 13
in-vivo (13) 13
lupus erythematosus, systemic - drug therapy (13) 13
middle aged (13) 13
sialic acids (13) 13
acute myeloid leukemia (12) 12
antibodies (12) 12
care and treatment (12) 12
lectins - metabolism (12) 12
leukemia, myeloid, acute - drug therapy (12) 12
lymphocytes (12) 12
mice, knockout (12) 12
b cells (11) 11
cell adhesion molecules (11) 11
health aspects (11) 11
immunoglobulins (11) 11
leukemia, myeloid, acute - metabolism (11) 11
molecular targeted therapy (11) 11
myelin-associated glycoprotein (11) 11
receptor (11) 11
research article (11) 11
sialic acid binding ig-like lectin 3 - antagonists & inhibitors (11) 11
signal transduction - immunology (11) 11
t-cells (11) 11
treatment outcome (11) 11
acute myeloid-leukemia (10) 10
cells (10) 10
disease (10) 10
identification (10) 10
inflammation (10) 10
leukemia, myeloid, acute - immunology (10) 10
lupus erythematosus, systemic - immunology (10) 10
macrophages (10) 10
organic acids (10) 10
protein binding (10) 10
sialic acid binding ig-like lectin 3 - genetics (10) 10
siglecs (10) 10
acute lymphoblastic leukemia (9) 9
antibodies, monoclonal - administration & dosage (9) 9
antigens, cd20 - immunology (9) 9
antigens, differentiation, b-lymphocyte - immunology (9) 9
antigens, differentiation, myelomonocytic - metabolism (9) 9
autoimmune diseases (9) 9
b-cells (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2016, Volume 375, Issue 8, pp. 740 - 753
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 122, Issue 17, pp. 3020 - 3029
Epratuzumab, a humanized anti-CD22 antibody, is currently in clinical trials of B-cell lymphomas and autoimmune diseases, demonstrating therapeutic activity in... 
RHEUMATOID-ARTHRITIS | HUMANIZED ANTI-CD22 ANTIBODY | SYSTEMIC-LUPUS-ERYTHEMATOSUS | SIGNAL-TRANSDUCTION MOLECULE | NK CELLS | PHASE-I/II | AUTOIMMUNE-DISEASES | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | PERIPHERAL-BLOOD | HEMATOLOGY | Lymphoma, Non-Hodgkin - immunology | Granulocytes - cytology | CD79 Antigens - immunology | Gene Expression - drug effects | Monocytes - cytology | CD79 Antigens - antagonists & inhibitors | Coculture Techniques | Humans | Receptors, Complement 3d - immunology | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Sialic Acid Binding Ig-like Lectin 2 - immunology | Antigens, CD19 - genetics | Monocytes - immunology | Lymphoma, Non-Hodgkin - pathology | Granulocytes - drug effects | Receptors, Complement 3d - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Immunotherapy | Receptors, Complement 3d - antagonists & inhibitors | Lupus Erythematosus, Systemic - drug therapy | Lupus Erythematosus, Systemic - immunology | Killer Cells, Natural - immunology | Antineoplastic Agents - pharmacology | B-Lymphocytes - pathology | Antigens, CD19 - immunology | Lymphoma, Non-Hodgkin - drug therapy | Phagocytosis - drug effects | Phagocytosis - immunology | Clinical Trials as Topic | Lymphoma, Non-Hodgkin - genetics | Monocytes - drug effects | B-Lymphocytes - drug effects | Killer Cells, Natural - cytology | B-Lymphocytes - immunology | Lupus Erythematosus, Systemic - genetics | Killer Cells, Natural - drug effects | CD79 Antigens - genetics | Primary Cell Culture | Lupus Erythematosus, Systemic - pathology | Granulocytes - immunology | Sialic Acid Binding Ig-like Lectin 2 - genetics
Journal Article
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 03/2013, Volume 52, Issue 13, pp. 3616 - 3620
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 05/2017, Volume 19, Issue 1, pp. 91 - 18
Journal Article
Journal of Immunology, ISSN 0022-1767, 02/2013, Volume 190, Issue 3, pp. 1158 - 1168
Pathogens use numerous methods to subvert host immune responses, including the modulation of host IL-10 production by diverse cell types. However, the B cell... 
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | LYMPHOCYTE DEVELOPMENT | DENDRITIC CELLS | IN-VIVO | IL-10 PRODUCTION | MONOCYTOGENES INFECTION | INTERLEUKIN-10 | IMMUNOLOGY | T-CELLS | SYSTEMIC AUTOIMMUNITY | TRANSGENIC MICE | T-Lymphocyte Subsets - immunology | Ovalbumin - immunology | Tumor Necrosis Factor-alpha - genetics | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Sialic Acid Binding Ig-like Lectin 2 - immunology | Antigens, CD19 - genetics | Adoptive Transfer | Listeria monocytogenes - immunology | Lymphocyte Depletion | Listeriosis - immunology | B-Lymphocyte Subsets - immunology | Interferon-gamma - genetics | Antibodies, Monoclonal - immunology | Antigens, CD20 - immunology | Nitric Oxide - biosynthesis | Cells, Cultured - drug effects | Specific Pathogen-Free Organisms | Antibodies, Monoclonal - pharmacology | Mice, Inbred C57BL | Listeria monocytogenes - isolation & purification | Mice, Transgenic | Immunity, Innate | Animals | B-Lymphocyte Subsets - metabolism | Interleukin-10 - genetics | Nitric Oxide - genetics | Interleukin-10 - biosynthesis | Listeriosis - microbiology | Cells, Cultured - metabolism | Mice | Immune Evasion - immunology | Immunity, Cellular | Interleukin-10 - immunology | Tumor Necrosis Factor-alpha - biosynthesis | Interferon-gamma - biosynthesis | Listeria monocytogenes | B cells | innate immunity | B10 cells | regulatory B cells
Journal Article
Journal of Autoimmunity, ISSN 0896-8411, 2012, Volume 39, Issue 3, pp. 161 - 167
Abstract Primary Sjögren's syndrome (pSS) is a chronic autoimmune systemic disease, characterized by a lymphoplasmocytic infiltration and a progressive... 
Allergy and Immunology | Rituximab | Biotherapy | Diagnosis | Sjögren's syndrome | B-cell | BAFF | Sjogren's syndrome | GLYCOSYLATION | IMMUNOLOGY | SALIVARY-GLANDS | IDENTIFICATION | DOUBLE-BLIND | GAMMA RECEPTOR AUTOANTIBODIES | CLASSIFICATION CRITERIA | LYMPHOCYTES | BLOOD | Salivary Glands - immunology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Salivary Glands - pathology | Cell Proliferation | Humans | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Sjogren's Syndrome - immunology | Antibodies, Monoclonal - therapeutic use | Sialic Acid Binding Ig-like Lectin 2 - immunology | fms-Like Tyrosine Kinase 3 - immunology | Lymphocyte Depletion | Autoantibodies - biosynthesis | B-Cell Activating Factor - antagonists & inhibitors | T-Lymphocytes - drug effects | B-Cell Activating Factor - immunology | B-Lymphocyte Subsets - immunology | T-Lymphocytes - pathology | Lacrimal Apparatus - pathology | Salivary Glands - drug effects | B-Lymphocyte Subsets - drug effects | Lacrimal Apparatus - drug effects | B-Lymphocyte Subsets - pathology | Lymphocyte Activation | Antibodies, Monoclonal - pharmacology | Sjogren's Syndrome - physiopathology | Lacrimal Apparatus - immunology | Autoantibodies - immunology | Sjogren's Syndrome - therapy | Sjogren's Syndrome - diagnosis | T-Lymphocytes - immunology | Autoimmunity | Viral antibodies | Care and treatment | Rheumatoid arthritis | Analysis | Antibodies | Lymphomas | T cells | Life Sciences | Immunology
Journal Article
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2151 - 2160
BACKGROUND Inotuzumab ozogamicin (InO), an anti‐CD22 antibody‐calicheamicin conjugate, demonstrated superior clinical activity versus standard‐of‐care (SOC)... 
clinical study | quality of life | acute lymphoblastic leukemia | inotuzumab ozogamicin | patient‐reported outcomes | patient-reported outcomes | SURVIVAL | ADULT PATIENTS | RELAPSE | IMPACT | ONCOLOGY | CLINICAL-TRIALS | QUALITY-OF-LIFE | BLINATUMOMAB | MONOCLONAL-ANTIBODIES | Dyspnea - chemically induced | Antibodies, Monoclonal, Humanized - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Fatigue - chemically induced | Neoplasm Recurrence, Local - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dyspnea - epidemiology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Fatigue - epidemiology | Sialic Acid Binding Ig-like Lectin 2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Quality of Life | Female | Precursor Cell Lymphoblastic Leukemia-Lymphoma - microbiology | Health Status | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Patient Reported Outcome Measures | Care and treatment | Analysis | Clinical trials | Outcome and process assessment (Health Care) | Acute lymphocytic leukemia | Research | Quality of life | Appetite | Calicheamicin | Statistical analysis | Acute lymphatic leukemia | Leukemia | Fatigue | Lymphatic leukemia | Patients | Confidence intervals | CD22 antigen | Randomization | Cytarabine | Dyspnea | Fludarabine | Lymphocytes B | Respiration | Mitoxantrone | Leukocytes (granulocytic) | Constipation | Public health | Cancer
Journal Article
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2015, Volume 97, pp. 72 - 84
Journal Article